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e216 - Correspondenceuse of the terms strong and weak opioids is not appropriate in
the setting of acute postoperative pain management, and that
as perioperative physicians, we should avoid the use of these
terms. More importantly, we need to acknowledge that all
opioids have the potential for causing subsequent opioid
dependence.
In addition to the harm to the individual patient caused by
subsequent opioid dependence, it is becoming increasingly
recognised that poor opioid stewardship also leads to opioid
diversion and subsequent opioid dependence in the commu-
nity.9 Currently, there are scant recommendations for safe
opioid disposal once patients are discharged from hospital in
the UK. Further social harm from opioid use/misuse arises
from Drug Driving. In 2015, Drug Driving finally became a
criminal offence in the UK; however, it has been argued that
the UK legislation is too lenient. In line with Australian guid-
ance, UK patients should be advised not to drive within 4
weeks of opioid dose adjustment.10
In summary we agree with the thrust of the review article
and that further evidence is urgently required to guide opioid
deprescribing strategies. In the meantime, in addition to the
strategies presented by Soffin and colleagues,1 we advocate:
 Postoperative opioid administration should be guided by
functional activity scores, and not by the NPS
 Opioids prescribed to opioid naı¨ve surgical patients should
explicitly not become repeat prescriptions.
 The duration of the opioid prescription needs to be realistic
and generally less than 5 days.
 Sustained/modified-release opioid preparations (including
transdermal) should be avoided in themanagement of acute
pain.
 Patients need to be given explicit advice on why and how to
dispose of excessmedication, and be informed how to taper/
wean their postoperative analgesia.
 Patients need to be warned about the dangers of drug
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*Corresponding author. E-mail: tarja.heiskanen@hus.fiEditordThe endogenous opioid system is involved in modula-
tion of both pain and pleasure.1 The opioid system also
contributes to mood regulation. In short-term use, exogenous
opioids have been suggested to increase positive mood andreduce negative feelings such as fear and anger.2,3 The effects
of opioids on emotional responses to external stimuli are
not fully understood. Opioids have been shown to reduce
perception of anger but leave perception of happiness in facial
Correspondence - e217expressions unaffected,4 or to have no effects on responses to
emotional stimuli.5 We examined the effects of remifentanil
and naloxone on subjective emotional responses evoked by
pleasant and unpleasant film clips. Our hypothesis was that
opioid administration either dampens the emotional responses
in general, or shifts them towards pleasure, whereas opioid
antagonism diminishes the perceived valence of the stimuli.
Male volunteers aged 20e35 yr (n¼31) completed a set of
subjective emotional rating questionnaires and then received
three i.v. infusions in the same order: remifentanil, placebo,
and naloxone. The participants were blinded to the sequenceFig 1. (a) Association between the mean valence and arousal ratings (s
and standard errors of mean for (b) self-reported valence and (c) arou
remifentanil and naloxone-induced changes in (d) self-reported vale
according to the remifentanil-induced change in valence ratings. N, nof the infusions. Remifentanil was administered at an effect-
site concentration of 1 ng ml1 using a target-controlled
infusion pump. The dose was chosen from a previous study
that showed an analgesic effect of this dose without excessive
sedation or desaturation.6 Naloxone was administered as a 5
mg kg1 i.v. bolus over 2 min followed by an infusion at 40 mg
kg1 h1, providing an estimated naloxone plasma concen-
tration of 10 ngml1.7 A saline bolus identical in volume to the
naloxone bolus was administered during the 2 min preceding
the remifentanil and saline infusions. Each infusion lasted 23
min and was followed by a 10-min washout period.cale: 0e1000) for each film clip during the saline condition. Means
sal. Asterisks show significant differences in contrast tests. Mean
nce and (e) arousal for each movie clip. The clips are arranged
egative clip; P, positive clip.8
e218 - CorrespondenceDuring each infusion, participants saw 10 film clips in a
random order and rated their experience of emotional valence
(pleasure) and arousal. The stimulus material consisted of
30 brief film clips with varying affective valence (strong
pleasureestrong displeasure) selected from a validated inter-
national database of well-known affective movies (http:/
nemo.psp.ucl.ac.be/FilmStim/).8 The film clips were grouped
into three approximately 20-min sets (1179 s, 1182 s, 1183 s)
with 10 clips in each, so that different videos with matched
emotional content could be shown during each drug block.
The average emotional valence of the three sets was matched
based on the ratings in the database. In a clip-wise (F2) anal-
ysis, subject-wise valence and arousal responses were
averaged for each individual clip. As the film clips were not
available in the native language (Finnish) of the subjects, they
were shown without sound.
Remifentanil significantly increased the experience of
pleasure, but not arousal, elicited by the film clips. This shift
was seen across stimuli that were both unpleasant and
pleasant. Naloxone shifted valence ratings for both negative
and positive clips towards neutral, but had no effect on mean
emotional valence or arousal ratings (Fig. 1). Analysis of clip-
wise mean ratings also revealed that on average, remifenta-
nil caused a positive shift in valence (but not arousal) for
nearly all clips. No differences in mean pleasure ratings
between naloxone and saline conditions were found. The
baseline personality or emotional status ratings were not
significantly correlated with the variance or arousal evalua-
tions. Four subjects reported nausea and five subjects reported
sedation after remifentanil administration.
Our results show that acute opioid administration shifts a
range of emotional responses to the positive direction, ampli-
fying positive and weakening negative feelings. Opioid antag-
onism shifted the valence ratings of both negative and positive
clips towards neutral, suggesting that naloxone might overall
diminish both positive and negative emotional experiences.
While these findings agree with a previous study, where
remifentanil increased the pleasantness ratings for neutral
pictures,9 our results differ from data on orally administered
opioids.4,5 The difference between remifentanil, morphine,
and oxycodone might be explained by the small oral doses
(10e20 mg) and the route of administration. Oral administra-
tion of an opioidmay be subject to inter-individual variation in
absorption and distribution of the drug. The peak plasma
concentration of oral oxycodone and morphine occurs at 1e2
h whereas with i.v. remifentanil it is achieved in 1e3 min.
Thus, the effects of oral opioids may be less predictable and
sensitive than those of target-controlled i.v. opioid infusions.
It is important to understand the role of opioids in the
modulation of emotional responses to sensory stimuli and
also in mood after both acute and prolonged administration.
Although small doses of acutely administered opioids cause
euphoria, the effects in chronic opioid use can be different. In
chronic opioid use, the brain reward system becomes altered,
resulting in neuroadaptation, tolerance, and less responsivity
to natural reward. Consequently, emotional reactivity is
blunted and the risk of depression increased.
Naloxone, like naltrexone, is a non-selective opioid recep-
tor antagonist. Previously, opioid antagonism has been shown
to cause no dampening of pleasure caused by emotional
stimuli, or to reduce the pleasure of attractive faces, gambling
rewards, or social bonding. These mixed results could be
explained by the different doses of opioid antagonists used
and the different emotional stimuli. As the dose of naloxone inour study was smaller than that in some of the previous
naloxone studies,3,10 the negative effects of naloxone on
emotional responses to both pleasant and unpleasant stimuli
did not reach statistical significance.
Together, these findings suggest that emotional responses
to external stimuli are mediated by the opioid system.
Short-term exogenous opioid administration increases the
emotional valence of the stimuli, while emotional arousal re-
mains unchanged. This may be one of the reasons behind the
first opioid experiences developing to an opioid use disorder
(e.g. after opioid use in the treatment of postoperative pain).Authors’ contributions
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